Scientific deep-dive
Three Domains Improved, Then One
A randomized trial found semaglutide improving three cognitive domains. After adjusting for sex and immune status, one was left, at exactly the significance threshold.
A randomized trial in people living with HIV found semaglutide improving three cognitive domains at 32 weeks. Then the authors adjusted for sex and immune status, and one was left, at P = .05, exactly on the line.[1] Both halves of that sentence are the finding, and only the first half travels.
Why this population
People living with HIV, even on effective antiretroviral therapy, carry higher rates of visceral fat accumulation, chronic inflammation and cognitive decline than people without HIV. Those three things are plausibly connected, and a drug that reduces the first two is a reasonable thing to test against the third.
The same group had already shown that semaglutide reduced weight, visceral fat and several inflammatory markers in this population. This trial asked whether cognition followed.
What was found, in order
Participants on antiretroviral therapy were randomized evenly to 32 weeks of semaglutide or placebo, double-blind, with cognitive function as the primary outcome, measured using a computerized screening instrument.
| Domain | Unadjusted | After adjusting for sex and CD4 count |
|---|---|---|
| Visuospatial | P = .01 | P = .05 |
| Naming and language | P = .05 | Not significant |
| Delayed recall | P = .04 | Not significant |
Adjustment is not a trick played on a result. Sex and CD4 count both plausibly relate to cognition and could differ between arms by chance in a 108-person trial; accounting for them is the more careful analysis. Two of the three findings did not survive it.
The adjusted result is the one the authors believed, and it is a single domain sitting on the threshold.
The paper’s own conclusion says semaglutide may have a beneficial impact on visuospatial cognitive function: hedged, and singular. That is an accurate description of what the table shows. The risk here is entirely in the retelling.
The question the abstract does not answer
It matters because of how thin the surviving margin is. A finding at exactly .05 in one of several domains, in 108 people, is the kind of result that exists to justify a larger trial rather than to change anything. That is also what a phase 2b study is for.
The inflammation route
The authors ran a mediation analysis and reported that semaglutide’s effect on the visuospatial score persisted while accounting for changes in two inflammatory markers (C-reactive protein and soluble CD163) at P = .04, which they read as the effect running through inflammation.
Mediation analysis tests whether a hypothesis is consistent with the data. It does not establish a causal pathway, because it rests on assumptions that trial data cannot verify. We set that out at more length in is it just the weight loss, and the same caution applies here with less data behind it.
What to take from it
- It is a phase 2b signal, not a treatment finding. One domain, at the threshold, in 108 people over 32 weeks.
- The screening instrument is not a full neuropsychological assessment. It is designed to detect change efficiently, not to characterize it.
- The question is worth pursuing. The biology is coherent and the population has a real unmet need.
- Anyone quoting “three cognitive domains improved” is quoting the unadjusted analysis and stopping before the sentence that follows it.
Frequently Asked Questions
References
- 1.Atieh O, Daher J, Abboud M, et al. Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial Clinical Infectious Diseases. 2026. PMID: 41098140.
Compare the sellers
Related research
Ozempic Brain Fog: What the Labels, Trials and Reports Show
Brain fog is not a listed side effect on the Ozempic, Wegovy, Mounjaro or Zepbound labels, and trials that tested thinking on GLP-1 drugs found no harm. The label-backed suspects are fatigue, dehydration, low blood sugar and too little food.
9 min read
What People Actually Do After Stopping
Average weight change in the year after stopping was +0.5% for people treated for obesity, and −1.3% for those treated for diabetes. That does not contradict the withdrawal trials. It answers a different question.
5 min read
The Day the Balloon Comes Out
An intragastric balloon is removed on a scheduled date, which makes it an unusually clean experiment in what happens when a weight intervention ends. One group began regaining. The other kept losing.
6 min read
GLP-1 Drugs and Headache: A Side Effect, and a Treatment
Headache is in the label’s adverse reactions table at 14% against 10% on placebo. A randomized trial using implanted pressure monitors also found a GLP-1 lowered intracranial pressure within hours.
7 min read
Two Studies, One Comparison, Two Answers
One real-world study found no cardiovascular difference between the two drugs. Another found semaglutide 29% better. Working out why they disagree is more useful than either answer.
6 min read
Dry Mouth on a GLP-1: Three Published Cases, and What to Tell Your Dentist
The most detailed published evidence that GLP-1 drugs cause dry mouth is three case reports, alongside an adverse-event reporting signal for semaglutide. Nobody has measured how often it happens, but reduced saliva raises decay risk regardless of cause, which is the part worth acting on.
5 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Direct Meds
Compounded semaglutide at $249/month
From $249/mo
Get started →HealthRX
Compounded semaglutide at $165/month after a $99 first month
From $165/mo
Get started →bmiMD
Starting below a standard dose, with microdose tiers
From $129/mo, prepaid
Get started →